IL-12 Therapeutic Optimization Service
Creative Biolabs directly addresses the systemic toxicity challenge that historically plagued interleukin-12 (IL-12) therapy. By leveraging decades of advanced protein and genetic engineering expertise, we offer integrated solutions to convert highly toxic systemic agents into safe, potent, tumor-restricted treatments, thereby significantly expanding the therapeutic window for solid tumor indications. Our services are focused on resolving the core safety-efficacy dilemma through precision engineering.
The IL-12 Dilemma: A Potent Mechanism, A Narrow Window
The main challenge of IL-12 therapy is its pleiotropic activity and uncontrolled JAK-STAT4 signaling, which triggers massive interferon-gamma (IFN-γ) production and subsequent cytokine release syndrome (CRS), even at the critically low maximum tolerated dose (MTD). This systemic toxicity, driven by IFN-γ, TNF-α, and chemokines (IP-10/MIG), prioritizes safety over the required therapeutic concentrations. Our engineering efforts resolve this pharmacokinetic (PK) and pharmacodynamic (PD) gap by ensuring tumor-specific accumulation, systemic inactivation in circulation, and controlled activation of full biological potency only within the diseased tumor microenvironment (TME).
Key Deliverables and Problem-Solving Capabilities
Elimination of Systemic CRS
Through strategies like protease-activated locks or non-secreting constructs, we prevent the uncontrolled systemic spillover of the highly toxic secondary cytokines (such as IFN-γ, TNF-α, and IP-10/MIG) that led to failure in early clinical trials.
Superior Tumor T Cell Recruitment and Activation
By achieving high concentrations of active IL-12 only within the TME, we maximize the localized expression of IFN-γ-inducible chemokines (MIG/CXCL9). These chemokines are crucial for attracting and sustaining cytotoxic CD8+ T cell infiltration, fundamentally altering the immune profile of cold tumors.
Integrated Platform Support for Optimal Delivery
Creative Biolabs provides comprehensive engineering for all major IL-12 formats, including targeted immunocytokines, oncolytic viruses, and advanced cellular therapies (e.g., CAR T/NK cells that function as local IL-12 micro-factories).
Contact our technical experts today to discuss how we can tailor a targeted delivery strategy for your specific tumor antigen and therapeutic goals.
Workflow
Our rigorous, stage-gated workflow is designed for clarity and efficiency, moving your IL-12 candidate from concept to IND-enabling data.
Publication
This review examines advanced strategies to augment solid tumor immunotherapy using IL-12, focusing on overcoming its dose-limiting systemic toxicity. Key innovative engineering approaches aim to transform "cold" tumors into "hot" ones by focusing IL-12's potent effects within the TME. These strategies include: protein engineering to create tumor-targeting immunocytokines and protease-activated prodrugs; genetic engineering for localized, inducible IL-12 expression in adoptive cell therapies (CAR-T); and the use of oncolytic viruses for direct intratumoral IL-12 delivery. These methods revitalize IL-12 as a powerful component of next-generation cancer immunotherapies.
Fig.1 Armored CAR T cells with inducible IL-12 knock-in for controlled anti-tumor immunity. 1
Why Choose Us?
Creative Biolabs is the industry leader in cytokine engineering, transforming pleiotropic agents like IL-12 into safe, effective precision medicines. Our engineered constructs provide a superior therapeutic index, validating a capacity to increase the MTD up to 30 times native IL-12, enabling truly therapeutic dosing. We offer unmatched targeting breadth, including protease-activated locks, ECM binding, and DNA/Histone targeting. Our integrated safety focus includes pioneering non-secreting/membrane-anchored IL-12 constructs for the ultimate elimination of systemic toxicity.
Experience the Creative Biolabs advantage firsthand and begin designing your safer, more potent IL-12 therapy—request a project quote today.
FAQs
Q: Why is targeted IL-12 superior to direct systemic IL-12 administration?
A: Targeted delivery ensures IL-12 is only active at the tumor site, minimizing off-target immune activation and allowing us to administer effective, localized doses that are systemically safe.
Q: Can your services help if my target tumor is considered "immunologically cold"?
A: Yes, absolutely. IL-12's primary function is to convert "cold" tumors into "hot" ones by massively upregulating IFN-γ and associated T cell-attracting chemokines.
Q: Which delivery platform is right for my project?
A: The optimal platform depends on your target, required dosing schedule, and disease indication. Immunocytokines offer easier manufacturing and systemic administration with a TME-activated safety lock.
Customer Review
-
Toxicity Eliminated
The non-secreting design completely solved the dose-limiting liver toxicity we previously observed with systemic rhIL-12. This is a genuine game-changer, confirmed by negligible circulating TNF-α levels in our safety studies. - Dr. L. H***s -
Cold Tumor Conversion
We had zero response to αPD-1 alone. Combining our checkpoint inhibitor with their OV-IL-12 platform resulted in complete and durable tumor regression, proving IL-12 delivery is the key to TME remodeling. - Dr. K. M***n
Related Services
To fully leverage the power of IL-12 and ensure a seamless pipeline, clients often require complementary services to achieve their final therapeutic goals.
Natural Killer (NK) Cell Immunophenotyping Service
Creative Biolabs' NK cell immunophenotyping service provides unparalleled insights by analyzing specific proteins and markers using state-of-the-art platforms, transcending basic cell enumeration for research and clinical trials.
Learn More →Next CAR-T Engineering
Creative Biolabs supplies cell and gene therapy products and devices, currently exploring engineered T cells, NK cells, and macrophages to induce anti-cancer/viral immune responses and regulate inflammation.
Learn More →How to Contact Creative Biolabs
Ready to revolutionize your immunotherapy program and overcome the limitations of systemic cytokine toxicity? Our scientific team is available to discuss your specific project needs and define the optimal IL-12 targeting strategy.
Contact Our Team for More Information and to Discuss Your Project
Reference
- Geils, Christian, and Katie L. Kathrein. "Augmentation of Solid Tumor Immunotherapy With IL‐12." The Journal of Gene Medicine 26.12 (2024): e70000. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1002/jgm.70000
Download our brochure